05Y Stock Overview
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Vivoryon Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.90 |
| 52 Week High | €22.05 |
| 52 Week Low | €8.38 |
| Beta | 2.01 |
| 1 Month Change | 0% |
| 3 Month Change | -3.57% |
| 1 Year Change | -54.87% |
| 3 Year Change | 41.95% |
| 5 Year Change | n/a |
| Change since IPO | 355.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| 05Y | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | -1.2% |
| 1Y | -54.9% | -19.8% | 1.8% |
Return vs Industry: 05Y underperformed the German Biotechs industry which returned -23.4% over the past year.
Return vs Market: 05Y underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| 05Y volatility | |
|---|---|
| 05Y Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 05Y has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 05Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 15 | Ulrich Dauer | www.vivoryon.com |
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer’s disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease; and for the treatment of cancer.
Vivoryon Therapeutics N.V. Fundamentals Summary
| 05Y fundamental statistics | |
|---|---|
| Market cap | €171.99m |
| Earnings (TTM) | -€12.65m |
| Revenue (TTM) | €10.76m |
16.0x
P/S Ratio-13.6x
P/E RatioIs 05Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 05Y income statement (TTM) | |
|---|---|
| Revenue | €10.76m |
| Cost of Revenue | €1.57m |
| Gross Profit | €9.20m |
| Other Expenses | €21.85m |
| Earnings | -€12.65m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.57 |
| Gross Margin | 85.42% |
| Net Profit Margin | -117.57% |
| Debt/Equity Ratio | 0% |
How did 05Y perform over the long term?
See historical performance and comparison